论文部分内容阅读
目的:探讨23价肺炎球菌多糖疫苗在支气管扩张患者的临床意义。方法:通过对28例支气管扩张患者注射23价肺炎球菌多糖疫苗后1年内肺部感染发生率及再发肺部感染的相距时间与对照组进行对比回顾性分析。结果:28例支气管扩张病例中在注射23价肺炎球菌多糖疫苗后1年内5例(17.85%),对照组35例支气管扩张病例1年内16例(45.70%)再发肺部感染,两者比较有显著性差异(P<0.05)。治疗组再发肺部感染相距时间为(168±92)d;对照组再发肺部感染相距时间为(157±94)d;两者比较无显著性差异(P>0.05)。结论:23价肺炎球菌多糖疫苗能有效地减少支气管扩张患者肺部感染复发率,是临床佐治支气管扩张患者的一个有效方法,值得临床推广。
Objective: To investigate the clinical significance of 23-valent pneumococcal polysaccharide vaccine in patients with bronchiectasis. Methods: The incidence of pulmonary infection within one year and the time interval between recurrent pulmonary infection within one year after the injection of 23-valent pneumococcal polysaccharide vaccine in 28 patients with bronchiectasis were retrospectively analyzed. Results: In 28 cases of bronchiectasis, 5 cases (17.85%) were within 1 year after injection of 23-valent pneumococcal polysaccharide vaccine and 16 cases (45.70%) within 1 year in 35 cases of bronchiectasis in control group. There was significant difference (P <0.05). The duration of recurrent pulmonary infection in the treatment group was (168 ± 92) d, and the time of pulmonary infection in the control group was (157 ± 94) days. There was no significant difference between the two groups (P> 0.05). CONCLUSION: The 23-valent pneumococcal polysaccharide vaccine can effectively reduce the recurrence rate of pulmonary infection in patients with bronchiectasis, which is an effective method for treating bronchiectasis in patients with bronchiectasis and is worthy of clinical promotion.